Erratum: Anti-inflammatory effects of total alkaloids from Rubus alceifolius Poir. on non-alcoholic fatty liver disease through regulation of the NF-?B pathway (International Journal of Molecular Medicine (2013) 31 (931-937) DOI: 10.3892/ijmm.2013.1281);Anti-inflammatory effects of total alkaloids from Rubus aleaefolius Poir. on non-alcoholic fatty liver disease through regulation of the NF-κB pathway

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 931-937

  Zhao, Jinyan ^a   Zheng, Haiyin ^a   Liu, Yan ^a   Lin, Jiumao ^a   Zhong, Xiaoyong ^a   Xu, Wei ^a   Hong, Zhenfeng ^a   Peng, Jun ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Nonalcoholic fatty liver disease; Nuclear factor B; Rubus aleaefolius Poir.; Total alkaloids

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALOID; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYCLOOXYGENASE 2; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; POLYENE PHOSPHATIDYLCHOLINE; TOTAL ALKALOID IN RUBUS ALEAEFOLIUS POIR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIVER METABOLISM; MALE; MEDICINAL PLANT; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUBUS ALEAEFOLIUS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875252003     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1628     Document Type: Erratum

References (32)

1. de Alwis NM and Day CP: Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48: S104-S112, 2008.
2. Angulo P, Keach JC, Batts KP and Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362, 1999.
3. Matteoni CA, Younossi ZM, Gramlich T, et al: Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419, 1999.
4. Teli MR, James OF, Burt AD, et al: The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 22: 1714-1719, 1995.
5. Day CP and James OFW: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
6. Cortez-Pinto H, de Moura MC and Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44: 197-208, 2006.
7. Chen CH, Huang MH, Yang JC, et al: Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 40: 745-752, 2006.
8. Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112-117, 2000.
9. Shen L, Fan JG, Shao Y, et al: Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9: 1106-1110, 2003.
10. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
11. Bugianesi E, McCullough AJ and Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42: 987-1000, 2005.
12. McCullough AJ: Update on non-alcoholic fatty liver disease. J Clin Gastroenterol 34: 255-262, 2002.
13. Lawrence T, Gilroy DW, Colville-Nash PR and Willoughby DA: Possible new role for NF-κB in the resolution of inflammation. Nat Med 7: 1291-1297, 2001.
14. Riehemann K, Behnke B and Schulze-Osthoff K: Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-κB. FEBS Lett 442: 89-94, 1999.
15. Renard P and Raes M: The proinflammatory transcription factor NF-kappa B: a potential target for novel therapeutical strategies. Cell Biol Toxicol 15: 341-344, 1999.
16. Makarov SS: NF-κB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6: 441-448, 2000.
17. Ywsilada E, Ustun O, Sezik E, et al: Inhibitory effect of Turkish folk remedies on inflammatory cytokines: interleukin-1α, interleukin-1β and tumor necrosis factor α. J Ethnopharmacol 58: 59-73, 1997.
18. Costantino L, Albasini A, Rastelli G and Benvenuti S: Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. Planta Med 58: 342-344, 1992.
19. Wang SY and Lin HS: Antioxidant activity in fruits and leaves of blackberry, raspberry, and strawberry varies with cultivar and development stage. J Agric Food Chem 48: 140-146, 2000.
20. Alonso R, Cadavid I and Calleja JM: A preliminary study of hypoglycemic activity of Rubus fruticosus. Planta Med 7 (Suppl): S102-S106, 1980.
21. Lee JH, Ham YA, Choi SH, et al: Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor. Arch Pharm Res 23: 338-343, 2000.
22. Rauha JP, Remes S, Heinonen M, et al: Antimicrobial effects of Finnish plant extracts containing flavonoids and other phenolic compounds. Int J Food Microbiol 56: 3-12, 2000.
23. Hong ZF, Li TJ and Zhao JY: Effect of total alkaloids of Rubus aleaefolius Poir on gene expressions of CYP2E2 and CYP3A1 in rats with acute liver injury. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 711-715, 2009 (In Chinese).
24. Lin JM, Zhao JY, Li TJ, et al: Hepatoprotection in a rat model of acute liver damage through inhibition of CY2E1 activity by total alkaloids extracted from Rubus alceifolius Poir. Int J Toxicol 30: 237-243, 2011.
25. Brunt EM: Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 22: 330-338, 2005.
26. Bellentani S and Tiribelli C: The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 35: 531-537, 2001.
27. Brunt EM: Pathology of nonalcoholic steatohepatitis. Hepatol Res 33: 68-71, 2005.
28. Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (Suppl 1): S99-S112, 2006.
29. Ye HZ, Hong ZF, Wang YH and Chen YH: Effects of crude extract of Rubus Alcaefolius Poir on experimental liver injury in rats. Chin Arch Tradit Chin Med 23: 829-831, 2005.
30. Yamaguchi K, Yang L, McCall S, et al: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366-1374, 2007.
31. Bonizzi G and Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288, 2004.
32. Baldwin AS Jr: The NF-kappaB and I-kappaB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.